Wells Fargo & Company Increases STAAR Surgical (NASDAQ:STAA) Price Target to $25.00

STAAR Surgical (NASDAQ:STAA) had its price objective raised by investment analysts at Wells Fargo & Company from $16.00 to $25.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has an “equal weight” rating on the medical instruments supplier’s stock. Wells Fargo & Company‘s price objective would suggest a potential downside of 22.51% from the stock’s current price.

Several other research firms have also commented on STAA. Stifel Nicolaus upped their price target on shares of STAAR Surgical from $18.00 to $31.00 and gave the company a “hold” rating in a research report on Thursday. Weiss Ratings lowered shares of STAAR Surgical from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, April 22nd. Mizuho upped their target price on shares of STAAR Surgical from $22.00 to $27.00 and gave the company a “neutral” rating in a report on Thursday. Jefferies Financial Group decreased their price target on shares of STAAR Surgical from $28.00 to $21.50 and set a “buy” rating on the stock in a research report on Wednesday, January 28th. Finally, Wedbush upgraded shares of STAAR Surgical from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $26.00 to $40.00 in a research note on Thursday. Three analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $27.81.

STAAR Surgical Price Performance

NASDAQ STAA opened at $32.26 on Friday. The stock has a market capitalization of $1.61 billion, a price-to-earnings ratio of -74.81 and a beta of 1.20. STAAR Surgical has a 1-year low of $15.59 and a 1-year high of $35.87. The business’s fifty day moving average price is $22.48 and its 200-day moving average price is $22.58.

STAAR Surgical (NASDAQ:STAA) last posted its quarterly earnings data on Wednesday, May 13th. The medical instruments supplier reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.07. STAAR Surgical had a positive return on equity of 3.33% and a negative net margin of 7.24%.The company had revenue of $93.52 million during the quarter, compared to analysts’ expectations of $78.72 million. During the same quarter in the prior year, the business earned ($1.10) earnings per share. STAAR Surgical’s revenue for the quarter was up 119.6% compared to the same quarter last year. Equities research analysts anticipate that STAAR Surgical will post -0.03 EPS for the current year.

Insider Activity

In related news, Director Broadwood Partners, L.P. bought 316,017 shares of the business’s stock in a transaction that occurred on Friday, March 13th. The stock was bought at an average cost of $18.61 per share, with a total value of $5,881,076.37. Following the completion of the purchase, the director owned 16,123,842 shares of the company’s stock, valued at approximately $300,064,699.62. The trade was a 2.00% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have purchased a total of 670,213 shares of company stock worth $12,266,249 in the last quarter. Company insiders own 39.90% of the company’s stock.

Institutional Investors Weigh In On STAAR Surgical

Several large investors have recently made changes to their positions in the company. New York Life Investment Management LLC purchased a new stake in STAAR Surgical in the 3rd quarter worth about $2,243,000. Alpine Associates Management Inc. bought a new stake in shares of STAAR Surgical in the 3rd quarter valued at about $24,535,000. Defender Capital LLC. bought a new position in shares of STAAR Surgical during the 4th quarter worth approximately $15,429,000. Versor Investments LP acquired a new position in STAAR Surgical during the 3rd quarter valued at about $5,708,000. Finally, Polar Asset Management Partners Inc. acquired a new position in shares of STAAR Surgical in the 3rd quarter valued at $3,359,000. 96.70% of the stock is owned by institutional investors.

STAAR Surgical News Roundup

Here are the key news stories impacting STAAR Surgical this week:

• Positive Sentiment: STAAR Surgical reported better-than-expected Q1 results, swinging to a profit of $0.10 per share versus a loss a year ago, while revenue jumped to $93.5 million and topped estimates. The beat suggests improving execution and stronger demand for its eye surgery products.
• Positive Sentiment: Management and earnings-call commentary pointed to improving conditions in China, cost discipline, and stabilized inventory, which investors are viewing as signs of a potential business recovery.
• Positive Sentiment: Analysts turned more constructive after the report: Wedbush upgraded STAAR Surgical to Outperform and raised its price target to $40, while Mizuho lifted its target to $27, reflecting renewed optimism around the company’s outlook.
• Neutral Sentiment: Needham maintained a Hold rating, highlighting that while recent trends look stable, visibility into the 2026 outlook is still limited.
• Negative Sentiment: Despite the upbeat quarter, a new regulatory risk disclosure and lingering uncertainty around future performance and valuation may temper enthusiasm if the recovery does not continue.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.